Inven2 are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority.
Since the establishment of Inven2 ten years ago, we have contributed to the establishment of 55 companies and 388 licenses alongside innovative researchers. This has led to NOK 500 million being channelled back to research and innovation.
Innovation motivated by patients
Jan Terje Andersen learnt about laboratory work when he was studying to become a biomedical laboratory scientist. Scientific curiosity led him to the Department of Biosciences at the University of Oslo.
A lecture by Professor Inger Sandlie decided his future career. Today, he is one of the researchers with the most innovations at Inven2.
Products on the market
Latest innovation news
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by...
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...